Therefore we utilized a well-known E-cadherin blocking antibody (SHEP8-7) and a pan-integrin antibody (CNT095) that targets human alpha-v-integrin and also was shown to block prostate tumor growth within bone [35]. Here, ITGAV is linked to prostate neoplasm.